NCT02258555 - Safety, Pharmacodynamics, Pharmacokinetics, and Efficacy of GS-9901 in Adults With Relapsed or Refractory Follicular Lymphoma, Marginal Zone Lymphoma, Chronic Lymphocytic Leukemia, or Small Lymphocytic Lymphoma | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

January 31, 2015

Primary Completion Date

August 31, 2015

Study Completion Date

August 31, 2015

Conditions

Follicular LymphomaChronic Lymphocytic LeukemiaSmall Lymphocytic LymphomaMarginal Zone Lymphoma

Interventions

DRUG

GS-9901

GS-9901 tablets administered orally

Trial Locations (6)

Innovative Clinical Research Institute, Whittier

City of Hope, Duarte

Cancer Care Center of Fresno, Fresno

Northwest Medical Specialties, Tacoma

Cancer Center Central Connecticut, Southington

Lombardi Cancer Center-Georgetown University, Washington D.C.